Arcturus therapeutics receives clearance from fda to begin h5n1 pandemic flu vaccine clinical trial

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a commercial messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the u.s. food and drug administration (fda) has issued a “study can proceed” notification for the company's investigational new drug (ind) application, arct-2304, a self-amplifying mrna (sa-mrna) vaccine ca.
ARCT Ratings Summary
ARCT Quant Ranking